Drugs / NDI-101150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05128487 | Nov 2021 → Feb 2025 overdue | gastroesophageal adenocarcinoma, non-small cell lung carcinoma, renal cell carcinoma | Nimbus Saturn, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDI-101150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05128487 ↗ |
| Action | Inhibit | “NDI-101150, a potent, selective HPK1 inhibitor” PMID 42097144 ↗ May 2026 |
| Route | Oral | “Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).” NCT05128487 ↗ |